JP2021530442A - 縮合三環系複素環化合物およびその治療上の使用 - Google Patents

縮合三環系複素環化合物およびその治療上の使用 Download PDF

Info

Publication number
JP2021530442A
JP2021530442A JP2020570791A JP2020570791A JP2021530442A JP 2021530442 A JP2021530442 A JP 2021530442A JP 2020570791 A JP2020570791 A JP 2020570791A JP 2020570791 A JP2020570791 A JP 2020570791A JP 2021530442 A JP2021530442 A JP 2021530442A
Authority
JP
Japan
Prior art keywords
alkyl
heterocyclyl
group
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530442A5 (https=
JPWO2020006432A5 (https=
Inventor
ドン リウ
レイ チェン
リンハン チュアン
プークェイ リ
シンチュー チャン
チュンイン ソン
ミラー マシュー
キユウ フ
ユナ ヤン
フェン ヘ
ウェイカン タオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of JP2021530442A publication Critical patent/JP2021530442A/ja
Publication of JP2021530442A5 publication Critical patent/JP2021530442A5/ja
Publication of JPWO2020006432A5 publication Critical patent/JPWO2020006432A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020570791A 2018-06-28 2019-06-28 縮合三環系複素環化合物およびその治療上の使用 Pending JP2021530442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862691208P 2018-06-28 2018-06-28
US62/691,208 2018-06-28
PCT/US2019/039860 WO2020006432A1 (en) 2018-06-28 2019-06-28 Fused tricyclic heterocycle compounds and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
JP2021530442A true JP2021530442A (ja) 2021-11-11
JP2021530442A5 JP2021530442A5 (https=) 2022-06-22
JPWO2020006432A5 JPWO2020006432A5 (https=) 2022-06-22

Family

ID=68987618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570791A Pending JP2021530442A (ja) 2018-06-28 2019-06-28 縮合三環系複素環化合物およびその治療上の使用

Country Status (7)

Country Link
US (1) US11535633B2 (https=)
EP (1) EP3813827A4 (https=)
JP (1) JP2021530442A (https=)
KR (1) KR20210025016A (https=)
CN (1) CN112351778B (https=)
TW (1) TW202019408A (https=)
WO (1) WO2020006432A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511540A (ja) * 2018-12-14 2022-01-31 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｓｔｉｎｇアゴニストとしての三環式化合物、ならびにその調製方法および医薬用途
JP7584802B2 (ja) 2018-08-24 2024-11-18 アドライ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性ｓｔｉｎｇタンパク質アゴニスト

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2929415T3 (es) 2018-05-25 2022-11-29 Incyte Corp Compuestos heterocíclicos tricíclicos como activadores de STING
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
CN111655682B (zh) * 2018-08-29 2024-05-31 杭州阿诺生物医药科技有限公司 一种高活性sting蛋白激动剂化合物
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
CA3149482A1 (en) 2019-08-02 2021-02-11 Mersana Therapeutics, Inc. Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
WO2021202984A1 (en) 2020-04-02 2021-10-07 Mersana Therapeutics, Inc. Antibody drug conjugates comprising sting agonists
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
CN115554303B (zh) * 2021-09-18 2024-07-09 上海科技大学 一种三环类化合物、其制备方法及其应用
CN119110800A (zh) * 2022-02-21 2024-12-10 健道生物医药有限公司 干扰素基因刺激因子（sting）调节剂及其组合物和方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08269058A (ja) * 1995-03-13 1996-10-15 Synthelabo Sa ピペリジン誘導体、その製造方法およびその治療における応用
FR2747678A1 (fr) * 1996-04-22 1997-10-24 Synthelabo Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique
JP2014508145A (ja) * 2011-02-09 2014-04-03 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３キナーゼ阻害剤としての複素環化合物
JP2017526731A (ja) * 2014-09-15 2017-09-14 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
WO2017175156A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175147A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2332239A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
CA2324090A1 (en) 1999-10-25 2001-04-25 Leviton Manufacturing Co., Inc. Electrical wiring device with multiple types of wire terminations
KR20080035576A (ko) * 2005-08-05 2008-04-23 아스트라제네카 아베 트리사이클릭 벤즈이미다졸 및 대사체 글루타메이트 수용체조절제로서 이들의 용도
EP2324044A4 (en) 2008-08-04 2012-04-25 Univ Miami STING (STIMULATOR OF INTERFERON GENES) AS A REGULATOR OF BORROWING IMMUNE REACTIONS
JP2015516989A (ja) 2012-04-30 2015-06-18 バーバー, グレン, エヌ.BARBER, Glen, N. 免疫反応の変調

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08269058A (ja) * 1995-03-13 1996-10-15 Synthelabo Sa ピペリジン誘導体、その製造方法およびその治療における応用
FR2747678A1 (fr) * 1996-04-22 1997-10-24 Synthelabo Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique
JP2014508145A (ja) * 2011-02-09 2014-04-03 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３キナーゼ阻害剤としての複素環化合物
JP2017526731A (ja) * 2014-09-15 2017-09-14 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
WO2017175156A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175147A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7584802B2 (ja) 2018-08-24 2024-11-18 アドライ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性ｓｔｉｎｇタンパク質アゴニスト
JP2022511540A (ja) * 2018-12-14 2022-01-31 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｓｔｉｎｇアゴニストとしての三環式化合物、ならびにその調製方法および医薬用途

Also Published As

Publication number Publication date
EP3813827A1 (en) 2021-05-05
CN112351778B (zh) 2023-04-04
US11535633B2 (en) 2022-12-27
KR20210025016A (ko) 2021-03-08
TW202019408A (zh) 2020-06-01
US20210300944A1 (en) 2021-09-30
WO2020006432A1 (en) 2020-01-02
EP3813827A4 (en) 2022-04-13
CN112351778A (zh) 2021-02-09

Similar Documents

Publication Publication Date Title
JP2021530442A (ja) 縮合三環系複素環化合物およびその治療上の使用
CN113840603B (zh) 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN110088099B (zh) 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法
WO2020108590A1 (zh) 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
JP7698658B2 (ja) がん治療のための置換オキソイソインドリン化合物
CN101356172A (zh) 激酶抑制剂
CN113121497A (zh) 用作RORγ调节剂的经过取代的四氢喹啉酮化合物
CN105579450A (zh) 新的吲嗪化合物、其制备方法和包含它们的药物组合物
CA2545425A1 (en) Azole-based kinase inhibitors
CN109983015B (zh) 6-吡唑-[1,2,4]三唑并[4,3-a]吡啶-3-酰胺类衍生物、其制备方法及其在医药上的应用
TW202007687A (zh) 經進一步取代之三唑并喹噁啉衍生物
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
WO2014157687A1 (ja) アセトアミド基を有する１，２，４－トリアジン－６－カルボキサミド誘導体
CN113195473B (zh) 三环化合物作为sting激动剂及其制备方法和医药用途
WO2024067694A1 (zh) 含氮杂环类化合物及其医药用途
CN103958526B (zh) 嘧啶二胺类衍生物、其制备方法及其在医药上的应用
CN112574212B (zh) 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN115703738A (zh) 含2-芳杂环取代的脲类化合物、其制备方法和用途
CN114126614A (zh) 作为prmt5抑制剂的杂环化合物
WO2024140970A1 (zh) 双环类化合物及其制备方法和应用
CN116249692B (zh) 吡唑类化合物及其制备方法和用途
CN119654317A (zh) 用于治疗癌症的取代双环杂芳基磺酰胺衍生物
CN109232533A (zh) 氮杂环类衍生物、其制备方法及其医药用途
WO2023134764A1 (zh) 含吡啶多环类衍生物、其制备方法和应用
HK40045549A (en) Fused tricyclic heterocycle compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231226